Xeris Pharmaceuticals Inc Stock News

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Stock analysts at Jefferies Financial Group cut their FY2025 earnings per share (EPS) estimates for shares of Xeris Pharmaceuticals in a research report issued to clients and investors on Thursday, November 11th. Jefferies Financial Group analyst D. Steinberg now forecasts that the company will post earnings per share of $0.32 []

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) price is hovering higher on Monday, November 15, jumping 7.47% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Xeris Pharmaceuticals (NASDAQ:XERS) had its target price raised by HC Wainwright from $4.00 to $4.25 in a report issued on Thursday, The Fly reports. The brokerage currently has a buy rating on the stock. Separately, Zacks Investment Research downgraded shares of Xeris Pharmaceuticals from a hold rating to a sell rating in a report on []

Xeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q3 2021 Results - Earnings Call Transcript

The biopharma is starting to put together a string of good news advances.

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusi

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use

Penny stocks with high marks from analysts right now. The post Top Penny Stocks Analysts Say To Buy, Targets Up To 200% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | P

The shares of Xeris Pharmaceuticals Inc (NASDAQ: XERS) increased 21.36% today. This is why it happened.

Xeris Pharmaceuticals Inc (NASDAQ: XERS) is trading significantly higher Monday after the company announced U.S. Food and Drug Administration approval of its New Drug Application for Gvoke for the

The FDA has approved Xeris Pharmaceuticals Inc's (NASDAQ:XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.  Gvoke Kit is the first rea

Are these penny stocks worth the risk? The post Trending Penny Stocks To Buy For Under $3 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The shares of Xeris Pharmaceuticals Inc (NASDAQ: XERS) increased by over 20% pre-market. This is why it happened.

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of -32.26% and -11.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use